Atossa Therapeutics And Quantum Leap Healthcare Initiates I-SPY 2 Clinical Trial To Evaluate (Z)-Endoxifen In Combination With Abemaciclib In Women With ER+/HER2- Breast Cancer
Author: Benzinga Newsdesk | April 15, 2024 08:39am
The new study arm will enroll approximately 20 women with newly diagnosed Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) invasive breast cancer. Participants will receive 40mg (Z)-endoxifen once daily in combination with 150mg abemaciclib twice daily for a total of 24 weeks prior to surgery.
Posted In: ATOS